Two years after Indivior was charged with engaging in an “illicit nationwide scheme to increase prescriptions” of an earlier version of its opioid addiction treatment, the drugmaker appears to have completed its journey to redemption.
It has invested in a new treatment for cannabis-related disorders, is branching out into alcohol misuse drugs, and is successfully growing sales of Sublocade, its once-a-month injection for opioid addiction. The shares have recovered almost 120 per cent since the start of this year. They closed on Friday at 223.4p, valuing the company at £1.7 billion.
However, Indivior is still trading at only about half the value it was in 2018 before it was hit with generic competition and then a US indictment. Its former chief executive, Shaun Thaxter, was